FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386531383> ?p ?o ?g. }

• W4386531383 endingPage "6317" @default.
• W4386531383 startingPage "6309" @default.
• W4386531383 abstract "An approach to a preventive HIV vaccine is induction of effective broadly neutralizing antibodies (bnAbs) and effector binding antibodies (bAbs). Preclinical studies suggest that trimeric envelope (Env) proteins may elicit nAbs, which led to the development of the recombinant gp145 subtype C Env protein (gp145 C.6980) immunogen. HVTN 122 was a Phase 1 trial that evaluated the safety, tolerability, and immunogenicity of gp145 C.6980 in adults. Healthy, HIV-1 seronegative adults received three intramuscular injections of gp145 C.6980 with aluminum hydroxide (alum) at months 0, 2, and 6 at either 300 mcg (high dose, n = 25) or 100 mcg (low dose, n = 15), or placebo/saline (placebo, n = 5). Participants were followed for 12 months. Forty-five participants were enrolled. High and low doses of the study protein were well-tolerated, with mild or moderate reactogenicity commonly reported. Only one adverse event (mild injection site pruritis) in one participant (low dose) was considered product-related; there were no dose-limiting toxicities. High and low dose recipients demonstrated robust bAb responses to vaccine-matched consensus gp140 Env and subtype-matched gp120 Env proteins two weeks post-last vaccination (response rates >90 %), while no responses were detected to a heterologous subtype-matched V1V2 antigen. No significant differences were seen between high and low dose groups. Participants in both experimental arms demonstrated nAb response rates of 76.5 % to a tier 1 virus (MW9635.26), but no responses to tier 2 isolates. Env-specific CD4 + T-cell responses were elicited in 36.4 % of vaccine recipients, without significant differences between groups; no participants demonstrated CD8 + T-cell responses. Three doses of novel subtype C gp145 Env protein with alum were safe and well-tolerated. Participants demonstrated bAb, Env-specific CD4 + T-cell, and tier 1 nAb responses, but the regimen failed to induce tier 2 or heterologous nAb responses. Clinical Trials Registration: NCT03382418" @default.
• W4386531383 created "2023-09-09" @default.
• W4386531383 creator A5000473108 @default.
• W4386531383 creator A5002215161 @default.
• W4386531383 creator A5004036928 @default.
• W4386531383 creator A5004410155 @default.
• W4386531383 creator A5009529720 @default.
• W4386531383 creator A5009785426 @default.
• W4386531383 creator A5010005336 @default.
• W4386531383 creator A5010695356 @default.
• W4386531383 creator A5013584124 @default.
• W4386531383 creator A5023829607 @default.
• W4386531383 creator A5026917180 @default.
• W4386531383 creator A5034536696 @default.
• W4386531383 creator A5055161733 @default.
• W4386531383 creator A5065306968 @default.
• W4386531383 creator A5070315953 @default.
• W4386531383 creator A5074003622 @default.
• W4386531383 creator A5083724331 @default.
• W4386531383 creator A5087375152 @default.
• W4386531383 creator A5092772905 @default.
• W4386531383 date "2023-10-01" @default.
• W4386531383 modified "2023-10-02" @default.
• W4386531383 title "Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1–uninfected adult participants in the US" @default.
• W4386531383 cites W1623081601 @default.
• W4386531383 cites W1964828486 @default.
• W4386531383 cites W1980973814 @default.
• W4386531383 cites W1985136634 @default.
• W4386531383 cites W1985145726 @default.
• W4386531383 cites W2014230220 @default.
• W4386531383 cites W2030129290 @default.
• W4386531383 cites W2082208556 @default.
• W4386531383 cites W2104197131 @default.
• W4386531383 cites W2113822425 @default.
• W4386531383 cites W2143421242 @default.
• W4386531383 cites W2152048324 @default.
• W4386531383 cites W2152640863 @default.
• W4386531383 cites W2157903295 @default.
• W4386531383 cites W2162803282 @default.
• W4386531383 cites W2196495924 @default.
• W4386531383 cites W2580738770 @default.
• W4386531383 cites W2775192867 @default.
• W4386531383 cites W2901685517 @default.
• W4386531383 cites W2926171264 @default.
• W4386531383 cites W2937097952 @default.
• W4386531383 cites W2972562701 @default.
• W4386531383 cites W30316958 @default.
• W4386531383 cites W3111091492 @default.
• W4386531383 cites W3138945586 @default.
• W4386531383 doi "https://doi.org/10.1016/j.vaccine.2023.07.046" @default.
• W4386531383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37679276" @default.
• W4386531383 hasPublicationYear "2023" @default.
• W4386531383 type Work @default.
• W4386531383 citedByCount "0" @default.
• W4386531383 crossrefType "journal-article" @default.
• W4386531383 hasAuthorship W4386531383A5000473108 @default.
• W4386531383 hasAuthorship W4386531383A5002215161 @default.
• W4386531383 hasAuthorship W4386531383A5004036928 @default.
• W4386531383 hasAuthorship W4386531383A5004410155 @default.
• W4386531383 hasAuthorship W4386531383A5009529720 @default.
• W4386531383 hasAuthorship W4386531383A5009785426 @default.
• W4386531383 hasAuthorship W4386531383A5010005336 @default.
• W4386531383 hasAuthorship W4386531383A5010695356 @default.
• W4386531383 hasAuthorship W4386531383A5013584124 @default.
• W4386531383 hasAuthorship W4386531383A5023829607 @default.
• W4386531383 hasAuthorship W4386531383A5026917180 @default.
• W4386531383 hasAuthorship W4386531383A5034536696 @default.
• W4386531383 hasAuthorship W4386531383A5055161733 @default.
• W4386531383 hasAuthorship W4386531383A5065306968 @default.
• W4386531383 hasAuthorship W4386531383A5070315953 @default.
• W4386531383 hasAuthorship W4386531383A5074003622 @default.
• W4386531383 hasAuthorship W4386531383A5083724331 @default.
• W4386531383 hasAuthorship W4386531383A5087375152 @default.
• W4386531383 hasAuthorship W4386531383A5092772905 @default.
• W4386531383 hasConcept C126322002 @default.
• W4386531383 hasConcept C142724271 @default.
• W4386531383 hasConcept C147483822 @default.
• W4386531383 hasConcept C159047783 @default.
• W4386531383 hasConcept C159654299 @default.
• W4386531383 hasConcept C197934379 @default.
• W4386531383 hasConcept C203014093 @default.
• W4386531383 hasConcept C204787440 @default.
• W4386531383 hasConcept C22070199 @default.
• W4386531383 hasConcept C27081682 @default.
• W4386531383 hasConcept C2777704310 @default.
• W4386531383 hasConcept C2778190748 @default.
• W4386531383 hasConcept C2778375690 @default.
• W4386531383 hasConcept C2779261636 @default.
• W4386531383 hasConcept C2779909307 @default.
• W4386531383 hasConcept C2780195530 @default.
• W4386531383 hasConcept C2780868878 @default.
• W4386531383 hasConcept C542903549 @default.
• W4386531383 hasConcept C71924100 @default.
• W4386531383 hasConceptScore W4386531383C126322002 @default.
• W4386531383 hasConceptScore W4386531383C142724271 @default.
• W4386531383 hasConceptScore W4386531383C147483822 @default.
• W4386531383 hasConceptScore W4386531383C159047783 @default.
• W4386531383 hasConceptScore W4386531383C159654299 @default.

• next